harpoon therapeutics is a pre-clinical stage biotechnology company co-founded by patrick bauerle, a pioneer in t-cell engagement, and luke evnin (mpm capital) in 2015 to develop and commercialize a novel class of t cell recruiting antibodies engage a patient’s own immune cells to fight cancer and other diseases. the world-class team of protein engineers and immunologists at harpoon have built upon the successful development of the bispecific (“bite™ or bispecific t cell engager”) antibody blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. harpoon’s tri-specific t-cell redirection platform -- tritac™ -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, car-t and other t-cell engaging approaches by improving  activity against